SCHEDULE 13G/A - Omada Health, Inc. (0001611115) (Subject)

10-Q - Omada Health, Inc. (0001611115) (Filer)

8-K - Omada Health, Inc. (0001611115) (Filer)

SCHEDULE 13G/A - Omada Health, Inc. (0001611115) (Subject)

DEFA14A - Omada Health, Inc. (0001611115) (Filer)

DEF 14A - Omada Health, Inc. (0001611115) (Filer)

S-8 - Omada Health, Inc. (0001611115) (Filer)

10-K - Omada Health, Inc. (0001611115) (Filer)

8-K - Omada Health, Inc. (0001611115) (Filer)

SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

Citizens initiated coverage of Omada Health with a rating of Mkt Outperform and set a new price target of $18.00

Wells Fargo initiated coverage of Omada Health with a rating of Equal Weight and set a new price target of $17.00

BMO Capital Markets initiated coverage of Omada Health with a rating of Outperform and set a new price target of $27.00

Robert W. Baird initiated coverage of Omada Health with a rating of Neutral and set a new price target of $24.00

Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00

Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00

Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00

Barclays initiated coverage of Omada Health with a rating of Overweight and set a new price target of $21.00

Needham initiated coverage of Omada Health with a rating of Buy and set a new price target of $23.00

Goldman initiated coverage of Omada Health with a rating of Buy and set a new price target of $29.00

SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, taking place in Miami, including a fireside chat on Wednesday, June 10, at 8:20 a.m. PST. The webcast will be available online at https://investors.omadahealth.com/news-events/events. A replay will also be available at the same link following the event. About Omada Health Omada Health (NASDAQ:OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at

SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada will offer its GLP‑1 Care Track, including clinical evaluation, prescribing, and ongoing medication management, to employers. This adds a new direct‑to‑employer channel alongside Omada's existing pharmacy benefit manager and cash‑pay pathways to make it easier for employers to offer weight loss medications with coordinated lifestyle support. Integrating with Lilly's Employer Connect allows Omada to provide another option with transparent net cost for Zepbound® and enables defined contribution l

Revenue up 42% Year over Year; Total Members Surpass One Million;Expanded Channels Now Include All Three of the Nation's Leading PBMs SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total Members: 1.02 million Total Members at the end of Q1, up 51% year over year, reinforcing Omada's role as an integrated, multi-condition cardiometabolic platform operating at scale.Revenue: $78 million in the first quarter, up 42% year over year.Omada joined Optum Rx's Weight Engage portfolio to help employers expand responsible,

SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP-1 Care Track lost, on average, 1.8 times more total weight and reduced their body fat percentage twice as much as the comparison group.1 The Omada members also saw an increase in muscle mass percentage and improvements in other well-being measures.1 These findings suggest that Omada's program may optimize the weight loss results of GLP-1s,1 mitigating a key risk of muscle loss associated with GLP-1s.2 Research has shown that during gradual weight loss from lifestyle interventions and older we

SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its first quarter 2026 results on Thursday, May 7, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-conf.media-server

SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual-first provider of between-visit care, today announced GLP-1 Flex Care, a new offering that will support employers looking to increase access to GLP-1 medications for obesity, including clinical evaluation, prescribing, and ongoing medical guidance and oversight. Members purchase their medications independently through cash-pay channels, helping employers limit their direct exposure to medication costs. Employee demand for GLP-1 medications continues to grow, but for many employers, the economics of full coverage remain out of reach.1 The majority of employers consider managing GLP-1 coverage and cost

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. 2025 Fourth Quarter and Full-Year HighlightsHighlights are for the fourth quarter and full year 2025, except where otherwise noted. Total members 886,000 at year end, up 55% year over year Revenue $76 million in the fourth quarter, up 58% year over

SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual-first, between-visit healthcare provider, today announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol,1 yet among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached a healthy LDL-C level (<70 mg/dL).2 This gap underscores a core challenge in traditional care models that are not designed to sustain the day-to-day behaviors required to improve cholesterol numbers over time. "High cholesterol rarely exists in isolation1,3

SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday, March 5, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-c

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Preliminary, unaudited revenue for the fourth quarter of 2025 is expected to be between $72 million and $74 million, representing an increase of 50% to 54% over the fourth quarter of 2024. For the full year 2025, preliminary revenue is expected to be between $256 million and $258 million, representing growth of 51% to 52% compared to 2024. Omada also announce

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associate

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology. In this role, he will lead Omada's clinical organization while advancing clinical quality, outcomes, strategy, and innovation across Omada's multi-condition platform. "Dr. Tsang's exceptional track record in building a virtual care delivery platform makes him the ideal clinical leader to help drive Omada's next phase of growth," said Sean Duffy, CEO and Co-Founder of Omada Heal

The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada's Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence a

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,1 challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications. The retrospective analysis included 816 members in Omada's GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months.1 At one year post-discontinuation members showed just 0.8% ave

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada's virtual physical therapy (PT) program to address musculoskeletal (MSK) conditions, Omada for Joint & Muscle Health, had lower utilization of total medical care and reduced MSK-related costs and encounters on average at 6 and 12 months compared to patients who used in-person PT (IP-PT). This study is believed to be one of the first peer-reviewed healthcare claims analyses to compare costs and utilization of virtual PT (V-PT) and IP-PT in treating MSK conditions while also accounting for the cost of the vir

SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in